BridgeBio Pharma (BBIO) Research & Development (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Research & Development data on file, last reported at $126.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 13.65% year-over-year to $126.6 million; the trailing twelve-month figure through Mar 2026 stood at $467.2 million (down 2.05% YoY), and the FY2025 full-year result was $452.0 million, down 10.76% from the prior year.
• Research & Development climbed to $126.6 million in Q1 2026, from $116.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $141.0 million in Q1 2024 to a low of $90.9 million in Q4 2022.
• A 5-year average of $114.1 million and a median of $112.9 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development declined 25.61% in 2022 and jumped 51.81% in 2024, its largest moves.
• Tracing BBIO's Research & Development over 5 years: stood at $90.9 million in 2022, then surged by 43.26% to $130.2 million in 2023, then increased by 0.1% to $130.4 million in 2024, then dropped by 10.69% to $116.4 million in 2025, then gained by 8.78% to $126.6 million in 2026.
• Business Quant data shows BBIO's Research & Development at $126.6 million in Q1 2026, $116.4 million in Q4 2025, and $112.9 million in Q3 2025.